NCTN BIQSFP ANBL1531 (NRT)

NCTN BIQSFP ANBL1531 (NRT)

• 批准号: 10892605
• 负责人: Douglas S. Hawkins
• 金额: $ 161.95万
• 依托单位: PUBLIC HEALTH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-01 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10892605
• 关键词: 1 year old; Acceleration; Acute Myelocytic Leukemia; Adolescent; Brain Stem Glioma; Canada; Cancer Center; Cause of Death; Cell Therapy; Child; Child Support; Childhood; Childhood Leukemia; Clinical; Clinical Trials; Clinical Trials Design; Collection; Complication; Country; Development; Diagnosis; Disease; Eligibility Determination; Enrollment; Family; Foundations; Functional disorder; Hormonal; Immunotherapy; Institution; Interdisciplinary Study; Laboratories; Late Effects; Malignant Childhood Neoplasm; Malignant Neoplasms; Mission; Molecular; National Cancer Institute; National Clinical Trials Network; Neuroblastoma; Organ; Outcome; Pediatric Hospitals; Pediatric Oncology Group; Pharmaceutical Preparations; Population Heterogeneity; Prognosis; Quality of life; Rare Diseases; Research; Research Personnel; Scientist; Second Primary Cancers; Site; Survival Rate; Tissues; Universities; Work; anticancer research; cancer therapy; chemotherapy; childhood cancer survivor; clinical translation; design; experience; health related quality of life; high risk; improved; improved outcome; innovation; member; novel therapeutic intervention; operation; reproductive; small molecule; translational study

PROJECT SUMMARY Since the introduction of chemotherapy for the treatment of childhood leukemia more than 60 years ago, the prognosis of childhood cancer has improved dramatically. The overall 5-year survival rate for childhood cancers, many of which were uniformly fatal in the pre-chemotherapy era, is now 84%. Progress for a number of childhood cancers, however, has been limited, with approximately 50% of children with acute myelogenous leukemia, 50% of children with high-risk neuroblastoma, and more than 90% of children with brainstem glioma, still succumbing to their disease. In the US, cancer remains the leading cause of death from disease in children greater than one year of age. Moreover, the late effects of cancer treatment, including permanent organ and tissue damage, hormonal and reproductive dysfunction and second cancers, are of special concern, with more than 40% of the 500,000 survivors of childhood cancer (estimated as of 2020) experiencing a significant health related quality of life complication from childhood cancer and its treatment. Thus, despite our advances, development of new therapeutic approaches must be a priority for childhood cancer basic, translational and clinical researchers. The Children’s Oncology Group (COG), the world’s largest organization devoted exclusively to childhood and adolescent cancer research, was founded 20 years ago. The COG’s multidisciplinary research team, comprised of more than 9,000 members, conducts research at more than 220 leading children’s hospitals, universities, and cancer centers. This proposal is for COG, as part of the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN), to continue its collaborative research work that supports the mission of improving the outcome for all children with cancer. The COG will design and conduct clinical-translational studies for children with cancer that builds on an increasing understanding of the molecular basis for pediatric malignancies and has the highest potential to improve the outcome. Using innovative clinical trial designs suitable for the study of rare diseases, we will study novel therapeutic approaches including but not limited to targeted small molecule drugs, immunotherapies and cellular therapies. The COG research portfolio importantly also includes clinical trials focused on improving the quality of life for children with cancer and childhood cancer survivors. As more than 90% of children diagnosed with cancer in the US are treated at COG member institutions, COG has the ability to offer a diverse population of children with cancer and their families the opportunity to participate in innovative research. This research effort includes allowing for collection and annotation of biospecimens from all children with cancer, providing the foundation for discovery and accelerating the most promising research efforts conducted in laboratories around the world. The proposal is for support of the COG Network Operations Center, clinician-scientists who develop and conduct research, and for member sites to participate through enrollment of eligible subjects.

项目摘要 自从60多年前引入化学疗法以治疗儿童白血病以来 儿童癌症的预后急剧改善。童年的总体5年生存率 癌症（其中许多癌症在化学疗法时代都统一致命，现在为84％。一个数字的进度 但是，儿童癌症的癌症受到限制，大约50％的急性骨髓儿童 白血病，有50％的高危神经母细胞瘤儿童，有90％以上的脑干神经胶质瘤儿童 仍然屈服于他们的疾病。在美国，癌症仍然是儿童疾病死亡的主要原因 大于一岁。此外，癌症治疗的后期作用，包括永久器官和 组织损伤，荷尔蒙和生殖功能障碍和第二次癌症特别关注，更多 在500,000个儿童癌症冲浪者中，超过40％的人（截至2020年估计） 儿童癌症及其治疗的相关生活质量并发症。那需要我们的进步， 开发新的治疗方法必须是儿童癌症基础，翻译和 临床研究人员。儿童肿瘤学小组（COG），世界上最大的组织 20年前成立于童年和青少年癌症研究。齿轮的 由9,000多名成员组成的多学科研究团队在220多个成员中进行研究 领先的儿童医院，大学和癌症中心。该建议是针对COG的，作为国家的一部分 癌症研究所（NCI）国家临床试验网络（NCTN）继续其协作研究工作 这支持了改善所有癌症儿童结果的使命。齿轮将设计和 对癌症儿童进行临床翻译研究，以日益了解 小儿恶性肿瘤的分子基础，并且具有改善结果的最高潜力。使用 创新的临床试验设计适用于稀有疾病的研究，我们将研究新疗法 方法包括但不限于靶向小分子药物，免疫疗法和细胞疗法。 COG研究组合重要的是，临床试验的重点是改善生活质量 患有癌症和儿童癌症的儿童生存。由于有90％以上被诊断出患有癌症的儿童 美国在COG成员机构接受治疗，COG有能力为潜水员提供儿童的人群 癌症及其家人有机会参加创新研究。这项研究工作包括 允许从所有癌症儿童那里收集和注释生物测量，从而提供基础 为了发现并加速了世界各地实验室进行的最有前途的研究工作。 该建议是为了支持COG网络运营中心，发展和 进行研究，并使会员站点通过符合条件的受试者的入学来参与。